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Background: Previous research has suggested that enteroviruses may be implicated in the 
development and persistence of Chronic Fatigue Syndrome (CFS). One method of investigating 
this topic has been to use a polio vaccination challenge, and a previous study showed that CFS 
patients had more shedding than healthy controls. There was no effect of the vaccination on the 
clinical condition or wellbeing of the CFS patients.  
Methods: In the previous study, the control group were more likely to have had a recent booster 
vaccination. This was controlled in the present study, where 18 CFS patients were randomly 
assigned to vaccination or placebo conditions. Nine healthy volunteers were also given the polio 
vaccination.  
Results: The results confirmed that vaccination had no negative effects on the CFS group. 
Although there was more virus shedding in the CFS polio group than in the control polio group, this 
difference was not significant.  
Conclusion: This study confirms that polio vaccination is not contraindicated in CFS patients but 
could not confirm that they are more susceptible to enterovirus infection. 
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There has been considerable research on 
enteroviruses and Chronic Fatigue Syndrome 
(CFS). The early studies led to conflicting results 
[1-3]. Enteroviruses can be broadly categorised 
into coxsackie viruses A and B, echoviruses, the 
polioviruses (types 1, 2, 3), and individual 
enterovirus serotypes. Early descriptions of CFS 
suggested that it resembled poliomyelitis [4]. 
Increased neutralising antibodies and IgM 
antibodies specific to coxsackie B viruses were 
found in CFS patients compared to healthy 
controls [5]. Enteroviruses were also more 
frequent in the faecal samples of those with CFS 
than controls [3]. This led to the suggestion that 
CFS may be caused by persistent enteroviral 
infection [6]. Early results provided mixed support 
for this view. In one study, CFS patients were 
found to show more enteroviral persistence in 
their muscles than healthy controls [7]. However, 
a later, larger study found no differences 
between the groups [8]. More recent studies (see 
[9, 10] for reviews) have also led to conflicting 
results [11-23].  
 
An alternative approach to CFS and 
enteroviruses has used the polio vaccine 
paradigm [24]. This paradigm allows one to 
examine enterovirus infection after administration 
of a live booster dose. It has previously been 
suggested that there is an association between 
vaccination and CFS [25]. The research 
examined the possible effects of live poliomyelitis 
re-vaccination on the symptoms and behaviour of 
CFS patients and healthy controls. In addition, 
differences in the two groups immune responses 
to the vaccine challenge were also investigated. 
Vaccination did not change the clinical condition 
of the CFS patients, and their T- and B-cell polio-
specific responses were no different from the 
healthy volunteers. However, the CFS patients 
did shed higher poliovirus levels, as identified by 
direct isolation, compared to the healthy controls. 
This study showed that live poliovirus vaccination 
in CFS patients is not contraindicated, which 
argues against the view that CFS is exacerbated 
by vaccinations. In addition, it is unlikely that a 
specific immune defect in response to 
enteroviruses can account for the pathogenesis 
of CFS. However, the increased poliovirus 
shedding in the CFS patients requires further 
study, and the underlying mechanisms still need 
to be identified. 
 
Many of the findings linking enteroviruses to CFS 
have been criticised in terms of poor 
methodology. In the original polio vaccine study, 
the control group had been given “booster” 
vaccinations more recently than the patients, 
which could plausibly account for the increased 
virus shedding. The present study addressed this 
by using a healthy control group that was 
matched with the CFS group in terms of the 
timing of the primary polio vaccination. The aims 
of the study were identical to the original                   
one, namely, to determine whether polio 
vaccination of CFS patients led to any adverse 
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Eighteen patients with CFS, diagnosed according 
to the Oxford criteria, were recruited randomly 
from a panel of those who had in the past or 
were currently attending the University of Wales 
College of Medicine (UWCM) CFS outpatient 
clinic. The demographic characteristics and 
illness history of these patients can be shown in 
Tables 1 and 2. In general, the profile of this 
sample was consistent with those of the typical 
patients attending the clinic from which they were 
recruited and of other CFS populations reported 
in the literature. A further nine individuals without 
CFS were recruited from the partners of the CFS 
patients taking part. 
 
2.2 Study Design 
 
Eighteen patients with CFS and nine individuals 
without CFS were recruited into a 28-day double-
blind study to determine any effects of poliovirus 
vaccination in individuals with CFS. On day 0, 
the healthy controls received the poliomyelitis 
vaccine (SmithKline Beecham), a live (Sabin) 
polio vaccine containing a mix of attenuated 
poliovirus types 1,2 and 3 (6 log10 poliovirus 1, 5 
log10 poliovirus 2 and 5.5 log10 poliovirus 3) 
while the patients with CFS were randomly 
allocated into either the placebo (sterile saline) or 
vaccine treatment groups and both the patients 
and experimenters who conducted the 
investigation were blind to which individuals 
received the vaccine. All individuals were 
followed up on four occasions thereafter (days 2, 











Table 1. Demographic characteristics of CFS patients and controls 
 
 CFS patients (vaccine) CFS patients (placebo) Controls 
(vaccine) 






Age Range 38 – 65 years 46 – 54 years 39 – 65 years 












Education level (%) 
 Primary education only 
 Left school before 16 
 Completed ‘O’ levels 
 Completed ‘A’ levels 
 At least one year at the 
University 


























Table 2. Clinical profile of the CFS patients and controls 
 






Mean duration of illness (months) 126.3 107.5 N/A 
Mean time since diagnosis (months) 73.8 52.0 N/A 
Current severity (%) 
Worse than at any stage 
Bad 
Bad with some recovery 
















Symptoms (%) – at time of study 
Physical weakness (Yes) 
Excessive fatigue 
Legs feeling heavy 
Muscle pain 










Sensitive to noise 









Loss of concentration 



































































































Pan-enterovirus and poliovirus-specific assays 
were developed and utilised for this part of the 
study. A method based on nucleic acid 
sequence-based amplification (NASBA) was 
found to be suitable for the analysis of poliovirus 
shedding [26]. NASBA has been found to be a 
suitable alternative to RT-PCR for the detection 
of enterovirus sequences. These kit-based 
reagents have enabled a wide range of 
laboratories to use molecular-based diagnostic 
procedures to identify RNA viruses. 
 
2.4 Clinical Assessment 
 
Subjective and objective assessments of the 
physical wellbeing of the sample were 
undertaken throughout the investigation by:  
 
 completion of a physical symptoms index 
at the start and a questionnaire completed 
at week 0 and week 4 of the study, which 
examined fatigue-related and somatic 
symptoms.  
 The objective assessments were 
undertaken by the clinician responsible for 
the CFS patient group, who arranged a 
consultation session for each patient on 
days 0 and 28. The clinician was blind to 
the treatment group into which each 
patient had been allocated. 
 
2.5 Psychosocial Assessment 
 
A series of questionnaires were administered to 
examine demographic and illness characteristics, 
current symptoms, and psychosocial measures. 
The second series of questionnaires were 
administered during the study: these examined: 
symptoms [24], mood [27], depression [28], state 
anxiety [29], emotional difficulties, cognitive 
difficulties, somatic symptoms, and fatigue [30]. 
 
2.6 Cognitive Assessment 
 
Subjective ratings of cognitive function [31] and 
objective assessments of cognitive functioning 
(simple reaction time and cognitive vigilance [32]) 




3.1 Virus Shedding Results 
 
Table 3 shows the virus shedding on days 2, 7, 
14 and 28 in the controls and the CFS vaccine 
and placebo groups. More patients than controls 
shed virus following vaccine challenge, but this 
effect was not significant. 
 
3.2 Effects of Vaccination on Mood, 
Symptoms, and Performance 
 
Table 4 shows the wellbeing scores for the 
controls and CFS vaccine and CFS placebo 
groups. There were no significant effects of 
vaccine challenge on subjective reports of health 
and wellbeing. 
 
Table 5 shows the cognitive performance scores 
for the controls and CFS groups. The CFS 
groups were slower and less accurate than the 
controls, but there were no effects of vaccination 




The present study was part of a larger 
programme on viral infections and CFS. Previous 
research has attempted to demonstrate a role for 
enteroviruses in the aetiology and pathogenesis 
of CFS. These studies have led to inconclusive 
results. However, there is evidence that CFS 
patients may be more susceptible to viral 
infections. In the first part of our research, 
prospective studies of upper respiratory tract 
illnesses (URTIs) were conducted [33, 34]. The 
results showed that CFS patients reported more 
URTIs, and the virology showed a greater 
number of infections confirming that the 
difference between the CFS and healthy groups 
was not due to a reporting bias. Indeed, similar 
virus identification rates were obtained in patient 
and control groups with clinical illnesses 
suggesting that identical mechanisms were in 
operation but that the CFS patients had more 
infections and illnesses. The results also showed 
that the CFS patients had more sub-clinical 
infections, which again supports the view that 
this group are particularly susceptible to acute 
infections. 
 
The present study was unable to replicate our 
previously reported finding that CFS patients are 
more likely to shed virus following polio vaccine 
challenge [24]. In the original study, the control 
group had been given “booster” vaccinations 
more recently than the patients, which plausibly 
accounts for our earlier results. The study did 
confirm that vaccination had no detrimental effect 
on the patients, which supports our earlier view 
that it is unlikely to cause the type of problem 











Table 3. Poliovirus shedding in patients and controls 
 
 Controls CFS Vaccine CFS Placebo 
Day 2 (%) 12 21 0 
Day 7 37 36 0 
Day 14 12 21 0 
Day 28 12 14 0 
 
Table 4. Baseline and post-vaccination questionnaire scores (means, s.d.s in parentheses) 
 
 Controls CFS Vaccine CFS placebo 















































































































































(1) High scores = greater impairment ; (2) Low scores = greater impairment 
 
Table 5. Baseline and post-vaccine scores for the performance tests (means and s.d.s) 
 
 Controls CFS Vaccine CFS Placebo 
Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 
SRT – mean RT msec 359.62 321.12 383.57 411.69 480.50 488.00 
Repeated digits vigilance task – 
Mean Hits 




Previous research has suggested that 
enteroviruses may be involved in the aetiology 
and pathogenesis of CFS. One method has used 
a polio vaccine challenge to examine possible 
differences in CFS patients ability to deal with 
viruses. An initial study showed no negative side 
effects of the polio vaccine but did demonstrate 
greater virus shedding in the CFS group. The 
present study confirmed that polio vaccination 
leads to no negative outcomes in the CFS group. 
However, it could not replicate the greater             
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